5'-Cytidine diphosphate choline, CDPC, CDP Choline, CDP-Choline, Citicholine, Citicolina, Cytidine 5-Diphosphocholine, Cytidine 5'-diphosphocholine, Cytidine (5') diphosphocholine, Cytidine Diphosphate Choline, Cytidine Diphosphocholine, Cytidinediphosphocholine.


Overview Information

Citicoline is a brain chemical that occurs naturally in the body. As a medicine, it is taken by mouth as a supplement or given as an injection into the vein (by IV) or as a shot into the muscle.

In Japan and Europe, Citicoline was originally used as a prescription drug to help improve memory, thinking, and brain function in people who are healing from a stroke. It is primarily used as a dietary supplement in the U.S.

Citicoline is taken by mouth or given as an injection to help memory loss due to aging, improve vision in people with glaucoma, and help with recovery in stroke patients. It is also used for Alzheimer disease, Parkinson disease, bipolar disorder, lazy eye, and other conditions of the brain. But there is no good scientific research to support these other uses.

How does it work?

Citicoline seems to increase a brain chemical called phosphatidylcholine. This brain chemical is important for brain function. Citicoline might also increase the amounts of other chemicals that send messages in the brain.


Uses & Effectiveness?

Possibly Effective for

  • Decline in memory and thinking skills that occurs normally with age. Taking citicoline seems to help memory loss in people aged 50 to 85 years.
  • A group of eye disorders that can lead to vision loss (glaucoma). Taking citicoline by mouth, as a shot, or as eye drops might improve vision in some people with glaucoma.
  • Stroke. Stroke patients who take citicoline by mouth or by IV within 24 hours of having the kind of stroke that is caused by a clot (ischemic stroke) are possibly more likely than other ischemic stroke patients to have a complete recovery within 3 months. Citicoline is most likely to work in people who can't receive a medicine called rtPA for their stroke.

Insufficient Evidence for

  • Alzheimer disease. Some evidence shows that taking citicoline by mouth might improve learning, memory, and the ability to process information in people with mild to moderate Alzheimer disease.
  • Lazy eye (amblyopia). Early research shows that giving citicoline as a shot for 15 days, or taking it by mouth for up to 1 year, might improve vision in people with a lazy eye.
  • Bipolar disorder. Early research shows that taking citicoline does not improve depression or manic symptoms in people with bipolar disorder and cocaine addiction.
  • Long-term blood flow problems in the brain (cerebrovascular diseases). There is some evidence that taking citicoline by mouth or injecting citicoline into the vein or muscle might improve memory and behavior in patients with long-term cerebrovascular diseases, such as stroke.
  • Cocaine use disorder. Early research shows that taking citicoline might reduce cocaine use in people with bipolar disorder and cocaine use disorder.
  • A mental state in which a person is confused and unable to think clearly. Early research shows that taking citicoline before and after surgery does not decrease confusion or improve thinking in elderly people.
  • Depression. There is some evidence that taking citicoline by mouth with an antidepressant called citalopram might help treat depression better than citalopram alone.
  • Bleeding within the skull (intracranial hemorrhage). Early research shows that citicoline can increase strength in people who are recovering from a bleed in the brain.
  • Vision loss due to blockage of the optic nerve (ischemic optic neuropathy). Early research shows that taking citicoline by mouth for 60 days might improve vision in people with ischemic optic neuropathy.
  • Injury to the brain, spine, or nerves (neurological trauma). It's unclear whether citicoline can decrease the chance of dying or improve memory, learning, and speaking in people who suffer an injury to the brain. Some early research shows that it might be helpful, while other research shows that it is not.
  • Parkinson disease. Some research shows that giving citicoline as a shot or taking it by mouth along with usual treatment might improve some of the symptoms of Parkinson disease, but not shaking (tremor).
  • Schizophrenia. Some early research shows that adding citicoline to standard drug therapy can improve "negative" symptoms in people with schizophrenia. These symptoms include difficulty expressing emotions, showing interest in others, feeling pleasure, and more. But taking citicoline might not help with "positive" symptoms, such as hallucinations and paranoia. Other early research shows that citicoline does not seem to improve sensory gating in people with schizophrenia. Sensory gating is the ability to block out repetitive noises that are not important, and some people with schizophrenia have trouble doing this.
  • Dementia caused by reduced blood flow to the brain (vascular dementia). Early research shows that citicoline does not help treat symptoms of vascular dementia.
  • Attention deficit-hyperactive disorder (ADHD).
  • Other conditions.
More evidence is needed to rate the effectiveness of citicoline for these uses.

Side Effects

Side Effects & Safety

When taken by mouth: Citicoline is POSSIBLY SAFE when taken by mouth for up to 90 days. Most people who take citicoline by mouth don't experience side effects. But some people can have side effects such as trouble sleeping (insomnia), headache, constipation, diarrhea, nausea, stomach pain, blurred vision, chest pains, and others. There isn't enough reliable information to know if taking citicoline by mouth long-term is safe or what the side effects might be.

When given by IV: Citicoline is POSSIBLY SAFE when given by a healthcare provider. Most people who are given citicoline by IV don't experience problematic side effects.

When given as a shot: Citicoline is POSSIBLY SAFE when given by a healthcare provider. Most people who are given citicoline as a shot don't experience problematic side effects.

Special Precautions & Warnings:

Pregnancy and breast-feeding: There isn't enough reliable information to know if citicoline is safe to use when pregnant or breast-feeding. Stay on the safe side and avoid use.

Children: Citicoline is POSSIBLY SAFE when taken by mouth for up to 1 year in children up to 13 years of age.



We currently have no information for CITICOLINE Interactions.



The following doses have been studied in scientific research:


  • For decline in memory and thinking skills that occurs normally with age: 1000-2000 mg of citicoline per day.
  • For a group of eye disorders that can lead to vision loss (glaucoma): 500-1600 mg per day.
  • For stroke: 500-2000 mg of citicoline per day starting within 24 hours of stroke.
  • Healthcare providers give citicoline as a shot into the muscle for a group of eye disorders that can lead to vision loss (glaucoma). Healthcare providers also give citicoline as an injection into the vein (by IV) for decline in memory and thinking skills that occurs normally with age and to improve recovery after a stroke.

View References


  • Adibhatla, R. M., Hatcher JF, and Dempsey RJ. Effects of citicholine on phospholipid and glutathione levels in transient cerebral ischemia. Stroke 2001;32(10):2376-2381.
  • Agnoli A, Fioravanti M, and Lechner H. Efficacy of CDP-Choline in chronic cerebral vascular diseases (CCVD). In: Zappia V, Kennedy EP, Nilsson BI, and Galletti PV. Novel Biochemical, Pharmacological, and Clinical Aspects of Cytidinediphosphocholine. New York: Elsevier Science;1985.
  • Aizawa, K., Kanai, T., Saikawa, Y., Takabayashi, T., Kawano, Y., Miyazawa, N., and Yamamoto, T. A novel approach to the prevention of postoperative delirium in the elderly after gastrointestinal surgery. Surg.Today. 2002;32(4):310-314. View abstract.
  • Alexandrov, A. V. Citicoline. Ferrer Internacional. Curr Opin.Investig.Drugs 2001;2(12):1757-1762. View abstract.
  • Alvarez, X. A., Laredo, M., Corzo, D., Fernandez-Novoa, L., Mouzo, R., Perea, J. E., Daniele, D., and Cacabelos, R. Citicoline improves memory performance in elderly subjects. Methods.Find.Exp.Clin.Pharmacol. 1997;19(3):201-210. View abstract.
  • Alvarez, X. A., Mouzo, R., Pichel, V., Perez, P., Laredo, M., Fernandez-Novoa, L., Corzo, L., Zas, R., Alcaraz, M., Secades, J. J., Lozano, R., and Cacabelos, R. Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer's disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion. Methods.Find.Exp.Clin.Pharmacol. 1999;21(9):633-644. View abstract.
  • Angeli G. Clinical study on Asonic (provisional name) [Sperimentazione clinica sul prodotto denominato provvisoriamente Asonic]. Rivista di Neuropsichiatria e Scienze Affini 1985;31:13-24.
  • Arranz, J. and Ganoza, C. Treatment of chronic dyskinesia with CDP-choline. Arzneimittelforschung. 1983;33(7A):1071-1073. View abstract.
  • Ataus S, Onal M, Zulkuf M, and et al. The effects of citicholine and lamotrigine alone and in combination following permanent middle cerebral artery occlusion in rats. International Journal of Neuroscience 2004;114(2):183-196.
  • Babb, S. M., Wald, L. L., Cohen, B. M., Villafuerte, R. A., Gruber, S. A., Yurgelun-Todd, D. A., and Renshaw, P. F. Chronic citicoline increases phosphodiesters in the brains of healthy older subjects: an in vivo phosphorus magnetic resonance spectroscopy study. Psychopharmacology.(Berl.) 2002;161(3):248-254. View abstract.
  • Barbagallo-Sangiorgi G, Ceruso D, Cuzzupoli MF, and et al. Double-blind, multicenter study on CDP-choline in patients with primary senile mental deterioration [Studio multicentrico in doppio cieco con Citicolina nel deterioramento mentale senile primitivo]. Invecchiamento Cerebrale e Cerebrovasculopatie Croniche 1988;
  • Berggren, D., Gustafson, Y., Eriksson, B., Bucht, G., Hansson, L. I., Reiz, S., and Winblad, B. Postoperative confusion after anesthesia in elderly patients with femoral neck fractures. Anesth.Analg. 1987;66(6):497-504. View abstract.
  • Bettini, R. and Gorini, M. [Reaction times during citicoline treatment]. Clin.Ter. 2002;153(4):247-250. View abstract.
  • Bonavita E, Chioma V, Dall'Oca P, and et al. Double-blind study on CDP-choline activity in primitive mild cognitive deterioration cases [Studio in doppio cieco sull'azione della citicolina nel cervello senile]. Minerva Psichiatrica 1983;24:53-62.
  • Bonavita, E. [Neuropsychological study of the senile brain during and after single and combined treatment with deanol and citicoline]. Clin.Ter. 6-15-1986;117(5):387-398. View abstract.
  • Brown, E. S., Gorman, A. R., and Hynan, L. S. A randomized, placebo-controlled trial of citicoline add-on therapy in outpatients with bipolar disorder and cocaine dependence. J Clin.Psychopharmacol. 2007;27(5):498-502. View abstract.
  • Campos, E. C., Schiavi, C., Benedetti, P., Bolzani, R., and Porciatti, V. Effect of citicoline on visual acuity in amblyopia: preliminary results. Graefes.Arch Clin.Exp.Ophthalmol. 1995;233(5):307-312. View abstract.
  • Capurso A, Capurso S, Panza F, and et al. Efficacy of cytidine diphosphate choline in patients affected by chronic cerebrovascular disease. Clinical Drug Investigation 1996;12(1):26-38.
  • Centrone, G., Ragno, G., and Calicchio, G. [Use of citicoline in high dosages in acute cerebrovascular disease]. Minerva Med 3-17-1986;77(11):371-373. View abstract.
  • Clark, W. M., Warach, S. J., Pettigrew, L. C., Gammans, R. E., and Sabounjian, L. A. A randomized dose-response trial of citicoline in acute ischemic stroke patients. Citicoline Stroke Study Group. Neurology. 1997;49(3):671-678. View abstract.
  • Clark, W. M., Wechsler, L. R., Sabounjian, L. A., and Schwiderski, U. E. A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology. 11-13-2001;57(9):1595-1602. View abstract.
  • Clark, W. M., Williams, B. J., Selzer, K. A., Zweifler, R. M., Sabounjian, L. A., and Gammans, R. E. A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke. 1999;30(12):2592-2597. View abstract.
  • Cubells, J. M. and Hernando, C. Clinical trial on the use of cytidine diphosphate choline in Parkinson's disease. Clin.Ther 1988;10(6):664-671. View abstract.
  • D'Orlando, K. J. and Sandage, B. W., Jr. Citicoline (CDP-choline): mechanisms of action and effects in ischemic brain injury. Neurol.Res 1995;17(4):281-284. View abstract.
  • Di, Trapani G. and Fioravanti, M. [Citicoline in the treatment of cognitive and behavioral disorders in pathologic senile decline]. Clin.Ter. 6-30-1991;137(6):403-413. View abstract.
  • Diaz, V., Rodriguez, J., Barrientos, P., Serra, M., Salinas, H., Toledo, C., Kunze, S., Varas, V., Santelices, E., Cabrera, C., Farias, J., Gallardo, J., Beddings, M. I., Leiva, A., and Cumsille, M. A. [Use of procholinergics in the prevention of postoperative delirium in hip fracture surgery in the elderly. A randomized controlled trial]. Rev.Neurol. 10-16-2001;33(8):716-719. View abstract.
  • Dinsdale, J. R., Griffiths, G. K., Castello, J., Maddock, J., Ortiz, J. A., and Aylward, M. CDP-choline: repeated oral dose tolerance studies in adult healthy volunteers. Arzneimittelforschung. 1983;33(7A):1061-1065. View abstract.
  • Dinsdale, J. R., Griffiths, G. K., Rowlands, C., Castello, J., Ortiz, J. A., Maddock, J., and Aylward, M. Pharmacokinetics of 14C CDP-choline. Arzneimittelforschung. 1983;33(7A):1066-1070. View abstract.
  • Eberhardt, R., Birbamer, G., Gerstenbrand, F., Rainer, E., and Traegner, H. Citicoline in the treatment of Parkinson's disease. Clin.Ther 1990;12(6):489-495. View abstract.
  • Falchi Delitata G, Falchi Delitata N, Casali R, and et al. Intermediate term, double-blind vs. placebo study of CDP-choline in cases with cognitive senile deterioration. Gazzetta Medica Italiana - Archivio Scienze Mediche 1984;143:789-810.
  • Fioravanti, M. and Yanagi, M. Cytidinediphosphocholine (CDP choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly. Cochrane Database.Syst.Rev. 2004;(2):CD000269. View abstract.
  • Fridman, E. A., Ottaviano, F., Fiol, M., Javelier, A., Perea, J. E., and Ameriso, S. F. [Neuroprotection in acute ischemic stroke. Practicability of guidelines for treatment]. Rev.Neurol. 5-1-2001;32(9):818-821. View abstract.
  • Iranmanesh, F. and Vakilian, A. Efficiency of citicoline in increasing muscular strength of patients with nontraumatic cerebral hemorrhage: a double-blind randomized clinical trial. J Stroke.Cerebrovasc.Dis. 2008;17(3):153-155. View abstract.
  • Kalisvaart, K. J., de Jonghe, J. F., Bogaards, M. J., Vreeswijk, R., Egberts, T. C., Burger, B. J., Eikelenboom, P., and van Gool, W. A. Haloperidol prophylaxis for elderly hip-surgery patients at risk for delirium: a randomized placebo-controlled study. J Am.Geriatr Soc 2005;53(10):1658-1666. View abstract.
  • León-Carrión J, Dominguez-Roldán JM, Murillo-Cabezas F, Dominguez-Morales MR, and Munoz-Sanchez MA. The role of citicholine in neuropsychological training after traumatic brain injury. NeuroRehabilitation 2000;14(1):33-40.
  • Liptzin B, Laki A, Garb, and et al. Donepezil in the Prevention and Treatment of Post-Surgical Delirium. American Journal of Geriatric Psychiatry 2005;13:1100-1106.
  • Lozano, Fernandez R. Efficacy and safety of oral CDP-choline. Drug surveillance study in 2817 cases. Arzneimittelforschung. 1983;33(7A):1073-1080. View abstract.
  • Lukas, S. E., Kouri, E. M., Rhee, C., Madrid, A., and Renshaw, P. F. Effects of short-term citicoline treatment on acute cocaine intoxication and cardiovascular effects. Psychopharmacology.(Berl.) 2001;157(2):163-167. View abstract.
  • Madariaga Aguirre L. A double-blind evaluation on a group of senile female patients, treated with CDP-choline. Revista de Psiquiatría y Psicología Médica 1978;13(5):331-342.
  • Marcantonio, E. R., Flacker, J. M., Wright, R. J., and Resnick, N. M. Reducing delirium after hip fracture: a randomized trial. J Am.Geriatr Soc 2001;49(5):516-522. View abstract.
  • Marti Masso, J. F. and Urtasun, M. Citicoline in the treatment of Parkinson's disease. Clin.Ther 1991;13(2):239-242. View abstract.
  • Motta L, Fichera G, Tiralosi G, and et al. CDP-choline in the treatment of chronic cerebrovasculopaties [La citicolina nel tratta mento delle cerebrovasculopatie croniche]. Unpublished Lederle (Cyanamid Italia) report. 1985;
  • Parisi, V., Coppola, G., Centofanti, M., Oddone, F., Angrisani, A. M., Ziccardi, L., Ricci, B., Quaranta, L., and Manni, G. Evidence of the neuroprotective role of citicoline in glaucoma patients. Prog.Brain.Res 2008;173:541-554. View abstract.
  • Parisi, V., Coppola, G., Ziccardi, L., Gallinaro, G., and Falsini, B. Cytidine-5'-diphosphocholine (Citicoline): a pilot study in patients with non-arteritic ischaemic optic neuropathy. Eur.J Neurol. 2008;15(5):465-474. View abstract.
  • Parisi, V., Manni, G., Colacino, G., and Bucci, M. G. Cytidine-5'-diphosphocholine (citicoline) improves retinal and cortical responses in patients with glaucoma. Ophthalmology. 1999;106(6):1126-1134. View abstract.
  • Pecori, Giraldi J., Virno, M., Covelli, G., Grechi, G., and De, Gregorio F. Therapeutic value of citicoline in the treatment of glaucoma (computerized and automated perimetric investigation). Int Ophthalmol. 1989;13(1-2):109-112. View abstract.
  • Petkov, V. D., Stancheva, S. L., Tocuschieva, L., and Petkov, V. V. Changes in brain biogenic monoamines induced by the nootropic drugs adafenoxate and meclofenoxate and by citicholine (experiments on rats). Gen.Pharmacol. 1990;21(1):71-75. View abstract.
  • Piccoli, F., Battistini, N., Carbonin, P., Curro, Dossi B., Fiori, L., La, Bella, V, Megna, G., Salvioli, G., and Fioravanti, M. CDP-choline in the treatment of chronic cerebrovasculopathies. Arch Gerontol Geriatr 1994;18(3):161-168. View abstract.
  • Radad K, Gille G, Xiaojing J, Durany N, and Rausch W-D. CDP-choline reduces dopaminergic cell loss induced by MPP-super(+) and glutamate in primary mesencephalic cell culture. International Journal of Neuroscience 2007;117(7):985-998.
  • Renshaw, P. F., Daniels, S., Lundahl, L. H., Rogers, V., and Lukas, S. E. Short-term treatment with citicoline (CDP-choline) attenuates some measures of craving in cocaine-dependent subjects: a preliminary report. Psychopharmacology.(Berl.) 1999;142(2):132-138. View abstract.
  • Rossi, M. and Zanardi, M. [An open study on the clinical efficacy of citicoline in patients with chronic cerebral vasculopathy]. Clin.Ter. 1993;142(2):141-144. View abstract.
  • Salvadorini F. Clinical evaluation of CDP-choline (Nicholin): Efficacy as antidepressant treatment. Therapeutic Research 1975;18(3):513-520.
  • Secades, J. J. and Lorenzo, J. L. Citicoline: pharmacological and clinical review, 2006 update. Methods.Find.Exp.Clin.Pharmacol. 2006;28 Suppl B:1-56. View abstract.
  • Secades, J. J., Alvarez-Sabin, J., Rubio, F., Lozano, R., Davalos, A., and Castillo, J. Citicoline in intracerebral haemorrhage: a double-blind, randomized, placebo-controlled, multi-centre pilot study. Cerebrovasc.Dis. 2006;21(5-6):380-385. View abstract.
  • Senin U and Fioravanti M. Clinical controlled study vs placebo of CDPcholine in a large group of aged patients with cerebrovascular dementia. Wyeth, Italy 2003;
  • Serra, F., Diaspri, G. P., Gasbarrini, A., Giancane, S., Rimondi, A., Tame, M. R., Sakellaridis, E., Bernardi, M., and Gasbarrini, G. [Effect of CDP-choline on senile mental deterioration. Multicenter experience on 237 cases]. Minerva Med. 1990;81(6):465-470. View abstract.
  • Siddiqi, N., Stockdale, R., Britton, A. M., and Holmes, J. Interventions for preventing delirium in hospitalised patients. Cochrane Database.Syst.Rev. 2007;(2):CD005563. View abstract.
  • Sinforiani E, Trucco M, Pacchetti C, and et al. Assessment of CDPcholine effects in patients with chronic cerebrovascular disease [Valutazione degli effetti della citicolina nella malattia cerebro-vascolare cronica]. Minerva Medica 1986;77(51):57.
  • Sinforiani, E., Trucco, M., Pacchetti, C., and Gualtieri, S. [Evaluation of the effects of citicoline in chronic cerebrovascular diseases]. Minerva Med 1-14-1986;77(1-2):51-57. View abstract.
  • Stramba-Badiale, M. and Scillieri, E. [Citicoline activity in senile mental decay]. Minerva Med 4-7-1983;74(14-15):819-821. View abstract.
  • Suryani L, Adnjana T, and Jensen G. Citicholine treatment of memory deficits in elderly people. International Journal of Geriatric Psychiatry 1988;3(3):235-236.
  • Tanaka, Y., Minematsu, K., Hirano, T., Hayashida, K., and Yamaguchi, T. [Effects of CDP-choline on dynamic changes in LCBF and cognitive function in demented subjects--an H2 15O-PET study]. Rinsho.Shinkeigaku. 1994;34(9):877-881. View abstract.
  • Trovarelli, G., de Medio, G. E., Dorman, R. V., Piccinin, G. L., Horrocks, L. A., and Porcellati, G. Effect of cytidine diphosphate choline (CDP-choline) on ischemia-induced alterations of brain lipid in the gerbil. Neurochem.Res 1981;6(8):821-833. View abstract.
  • Virno, M., Pecori-Giraldi, J., Liguori, A., and De, Gregorio F. The protective effect of citicoline on the progression of the perimetric defects in glaucomatous patients (perimetric study with a 10-year follow-up). Acta Ophthalmol.Scand.Suppl 2000;(232):56-57. View abstract.
  • Warach, S., Pettigrew, L. C., Dashe, J. F., Pullicino, P., Lefkowitz, D. M., Sabounjian, L., Harnett, K., Schwiderski, U., and Gammans, R. Effect of citicoline on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging. Citicoline 010 Investigators. Ann.Neurol. 2000;48(5):713-722. View abstract.
  • Xiong, Y., Liu, X., Wang, Y., and Du, Y. Cloning of cytidine triphosphate: phosphocholine cytidylyltransferase mRNA upregulated by a neuropeptide arginine-vasopressin((4-8)) in rat hippocampus. Neurosci.Lett. 4-7-2000;283(2):129-132. View abstract.
  • Yashima, K., Takamatsu, M., and Okuda, K. Intestinal absorption of cytidine diphosphate choline and its changes in the digestive tract. J Nutr Sci Vitaminol.(Tokyo) 1975;21(1):49-60. View abstract.
  • Adibhatla RM, Hatcher JF. Citicoline decreases phospholipase A2 stimulation and hydroxyl radical generation in transient cerebral ischemia. J Neurosci Res 2003;73:308-15. View abstract.
  • Adibhatla RM, Hatcher JF. Citicoline mechanisms and clinical efficacy in cerebral ischemia. J Neurosci Res 2002;70:133-9. View abstract.
  • Aidelbaum R, Labelle A, Baddeley A, Knott V. Assessing the acute effects of CDP-choline on sensory gating in schizophrenia: a pilot study. J Psychopharmacol. 2018;32(5):541-51. View abstract.
  • Babb SM, Appelmans KE, Renshaw PF, et al. Differently effect of CDP-choline on brain cytosolic choline levels in younger and older subjects as measured by magnetic resonance spectroscopy. Psychopharmacology (Berl) 1996;127:88-94. View abstract.
  • Barrachina M, Dominguez I, Ambrosio S, et al. Neuroprotective effect of citicoline in 6-hydroxydopamine-lesioned rats and in 6-hydroxydopamine-treated SH-SY5Y human neuroblastoma cells. J Neurol Sci 2003;215:105-10. View abstract.
  • Brown ES, Todd JP, Hu LT, et al. A randomized, double-blind, placebo-controlled trial of citicoline for cocaine dependence in bipolar I disorder. Am J Psychiatry 2015;172(10):1014-21. View abstract.
  • Clark BC, Georgekutty J, Berul CI. Myocardial ischemia secondary to synthetic cannabinoid (K2) use in pediatric patients. J Pediatr 2015;167(3):757-61.e1. View abstract.
  • Cohen RA, Browndyke JN, Moser DJ, et al. Long-term citicoline (cytidine diphosphate choline) use in patients with vascular dementia: Neuroimaging and neuropsychological outcomes. Cerebrovasc Dis 2003;16:199-204. View abstract.
  • Conant R, Schauss AG. Therapeutic applications of citicoline for stroke and cognitive function in the elderly: A review of the literature. Altern Med Rev 2004;9:17-31. View abstract.
  • Cotroneo AM, Castagna A, Putignano S, et al. Effectiveness and safety of citicoline in mild vascular cognitive impairment: the IDEALE study. Clin Interv Aging 2013;8:131-7. View abstract.
  • Dávalos A, Alvarez-Sabín J, Castillo J, et al. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet 2012;380(9839):349-57. View abstract.
  • Davalos A, Castillo J, Alvarez-Sabin J, et al. Oral citicoline in acute ischemic stroke: An individual patient date pooling analysis of clinical trials. Stroke 2002;33:2850-7. View abstract.
  • Dempsey RJ, Raghavendra Rao VL. Cytidinediphosphocholine treatment to decrease traumatic brain injury-induced hippocampal neuronal death, cortical contusion volume, and neurological dysfunction in rats. J Neurosurg 2003;98:867-73. View abstract.
  • El Sayed I, Zaki A, Fayed AM, Shehata GM, Abdelmonem S. A meta-analysis of the effect of different neuroprotective drugs in management of patients with traumatic brain injury. Neurosurg Rev 2018;41(2):427-38. View abstract.
  • Fioravanti M, Yanagi M. Cytidinediphosphocholine (CDP-choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly. Cochrane Database Syst Rev 2005;(2):CD000269. View abstract.
  • Ghajar A, Gholamian F, Tabatabei-Motlagh M, et al. Citicoline (CDP-choline) add-on therapy to risperidone for treatment of negative symptoms in patients with stable schizophrenia: a double-blind, randomized placebo-controlled trial. Hum Psychopharmacol. 2018;33(4):e2662. View abstract.
  • Licata SC, Penetar DM, Ravichandran C, et al. Effects of daily treatment with citicoline: a double-blind, placebo-controlled study in cocaine-dependent volunteers. J Addict Med 2011;5(1):57-64. View abstract.
  • Ottobelli L, Manni GL, Centofanti M, et al. Citicoline oral solution in glaucoma: is there a role in slowing disease progression? Ophthalmologica 2013;229(4):219-26. View abstract.
  • Parisi V, Centofanti M, Ziccardi L, et al. Treatment with citicoline eye drops enhances retinal function and neural conduction along the visual pathways in open angle glaucoma. Graefes Arch Clin Exp Ophthalmol 2015;253(8):1327-40. View abstract.
  • Pawar PV, Mumbare SS, Patil MS, Ramakrishnan S. Effectiveness of the addition of citicoline to patching in the treatment of amblyopia around visual maturity: a randomized controlled trial. Indian J Ophthalmol 2014;62(2):124-9. View abstract.
  • Rejdak R, Toczolowski J, Krukowski J, et al. Oral citicoline treatment improves visual pathway function in glaucoma. Med Sci Monit 2003;9:PI24-8. View abstract.
  • Roohi-Azizi M, Arabzadeh S, Amidfar M, et al. Citicoline combination therapy for major depressive disorder: a randomized, double-blind, placebo-controlled trial. Clin Neuropharmacol 2017;40(1):1-5. View abstract.
  • Savci V, Goktalay G, Cansev M, et al. Intravenously injected citicoline increases blood pressure and reverses hypotension in haemorrhagic shock: effect is mediated by central cholinergic activation. Eur J Pharmacol 2003;468:129-39. View abstract.
  • Secades JJ, Alvarez-Sabín J, Castillo J, et al. Citicoline for acute ischemic stroke: a systematic review and formal meta-analysis of randomized, double-blind, and placebo-controlled trials. J Stroke Cerebrovasc Dis 2016;25(8):1984-96. View abstract.
  • Shi PY, Zhou XC, Yin XX, Xu LL, Zhang XM, Bai HY. Early application of citicoline in the treatment of acute stroke: a meta-analysis of randomized controlled trials. J Huazhong Univ Sci Technolog Med Sci 2016;36(2):270-7. View abstract.
  • Sobrado M, Lopez MG, Carceller F, et al. Combined nipodimine and citicoline reduce infarct size, attenuate apoptosis, and increase BCL-2 expression after focal cerebral ischemia. Neuroscience 2003;118:107-13. View abstract.
  • Spiers PA, Myers D, Hochanadel GS, et al. Citicoline improves verbal memory in aging. Arch Neurol 1996;53:441-8. View abstract.
  • Teather LA, Wurtman RJ. Dietary cytidine (5)-diphosphocholine supplementation protects against development of memory deficits in aging rats. Prog Neuropsychopharmacol Biol Psychiatry 2003;27:711–17. View abstract.
  • Trimmel H, Majdan M, Wodak A, Herzer G, Csomor D, Brazinova A. Citicoline in severe traumatic brain injury: indications for improved outcome: a retrospective matched pair analysis from 14 Austrian trauma centers. Wien Klin Wochenschr. 2018;130(1-2):37-44. View abstract.
  • Weiss GB. Metabolism and actions of CDP-choline as an endogenous compound and administered exogenously as citicoline. Life Sci 1995;56:637-60. View abstract.
  • Zemel MB, Thompson W, Milstead A, et al. Calcium and dairy acceleration of weight and fat loss during energy restriction in obese adults. Obes Res 2004;12:582–90. View abstract.
  • Zweifler RM. Membrane stabilizer: Citicoline. Curr Med Res Opin 2002;18:s14-s17. View abstract.

Vitamins Survey

Have you ever purchased CITICOLINE?

Did you or will you purchase this product in-store or online?

Where did you or where do you plan to purchase this product?

Where did you or where do you plan to purchase this product?

What factors influenced or will influence your purchase? (check all that apply)

Vitamins Survey

Where did you or where do you plan to purchase this product?

Do you buy vitamins online or instore?

What factors are most important to you? (check all that apply)

This survey is being conducted by the WebMD marketing sciences department.Read More

More Resources for CITICOLINE

CONDITIONS OF USE AND IMPORTANT INFORMATION: This information is meant to supplement, not replace advice from your doctor or healthcare provider and is not meant to cover all possible uses, precautions, interactions or adverse effects. This information may not fit your specific health circumstances. Never delay or disregard seeking professional medical advice from your doctor or other qualified health care provider because of something you have read on WebMD. You should always speak with your doctor or health care professional before you start, stop, or change any prescribed part of your health care plan or treatment and to determine what course of therapy is right for you.

This copyrighted material is provided by Natural Medicines Comprehensive Database Consumer Version. Information from this source is evidence-based and objective, and without commercial influence. For professional medical information on natural medicines, see Natural Medicines Comprehensive Database Professional Version.
© Therapeutic Research Faculty .